Price History

Hover for the daily close. The dotted line marks the period open.

Compare GPCR with… →

GPCR Key Statistics

As of Sep 4, 2026

Trading

Open: $47.26
Previous Close: $47.34
Day's Range: 46.73–48.06
52-Week Range: 20.04–94.90
Volume: 281.70K
Beta: −1.52

Valuation

Market Cap: $3.38B
P/E Ratio: unprofitable
EPS (ttm): −3.02

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$141.20M
Profit margin: 0.00%
Shares Outstanding: 71.31M
1-Year Return: +139.57%

Dividend and dates

Earnings Date: November 5, 2026estimated
Avg Volume: 746.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GPCR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+56.77%−33.46%+156.45%−31.93%

2023*202420252026*

Year	Return
2026 (partial year)	−31.93%
2025	+156.45%
2024	−33.46%
2023 (partial year)	+56.77%

As of September 4, 2026.

GPCR Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$141.20M	—
2024	$0.00	−$122.53M	—
2023	$0.00	−$89.62M	—
2022	$0.00	−$51.32M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$186.81M	−$141.20M	—
2024	$0.00	—	−$158.23M	−$122.53M	—
2023	$0.00	—	−$102.78M	−$89.62M	—
2022	$0.00	—	−$52.56M	−$51.32M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GPCR Valuation vs Biotechnology Median

Median of 656 stocks

Metric	GPCR	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Structure Therapeutics Inc. (GPCR) at $3.38B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 281.

GPCR last closed at $47.34 on September 4, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $20.04 to $94.90. The latest close sits 136.23% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $141.20M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −3.02.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +139.57%. Measured over 3 years, that is +17.25% a year compounded. Beta against the wider market is reported at −1.52. Annualized volatility over the trailing 3 years is 99.61%.

Growth & Income

No dividend is on file for GPCR.

2026 is still running; the price is −31.93% year to date. Across the complete calendar years on file, 2025 returned +156.45% and 2024 returned −33.46%.

Peer Comparison

Structure Therapeutics Inc. (GPCR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Structure Therapeutics Inc.	GPCR	$3.38B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Structure Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Visit website →

Structure Therapeutics Inc. (GPCR) Stock Analysis